In the latest close session, Merck (MRK) was up +1.07% at $149.88. The stock outpaced the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of 0.69%, while the tech-heavy Nasdaq appreciated by 1.05%.
The pharmaceutical company's stock has dropped by 1.73% in the past month, falling short of the Medical sector's gain of 3.5% and the S&P 500's gain of 0.97%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 29, 2026. The company is expected to report EPS of $2.12, down 17.83% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $17.23 billion, showing a 0.25% drop compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.66 per share and a revenue of $67.1 billion, indicating changes of -70.38% and +3.21%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.83% lower. Merck currently has a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Merck is holding a Forward P/E ratio of 55.8. This signifies a premium in comparison to the average Forward P/E of 17.25 for its industry.
One should further note that MRK currently holds a PEG ratio of 6.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.04.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 219, putting it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).